← Leaderboards
Edda Frauke Spiekerkoetter
Stanford University
$6,465,471
Attributed
$6,482,721
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,482,721 · 5
By mechanism
R01$5,842,041 · 3
K08$606,180 · 1
R13$34,500 · 1
Top collaborators
- Joyce Ming Cao Teng1 shared
Most similar at Stanford University
Same institution · by research overlap
- Jayakar V Nayak$2,392,495
- Marlene Rabinovitch$40,032,014
- Mark Mercola$44,191,191
- David P Marciano$1,140,116
- Thomas F Serwold$5,079,780
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsLungPharmaceutical PreparationsSignal TransductionPulmonary Arterial HypertensionPreventLinkPulmonary HypertensionNovel TherapeuticsMissionHypoxiaHigh Throughput ScreeningPenetranceTubeUnited States National Institutes Of HealthFk506ApoptosisClinical TrialsBlood VesselsHeart FailureBone Morphogenetic Protein ReceptorsLeftMessenger RnaFda Approved
Grant awards (18)
Understanding and targeting molecular and cellular events responsible for pulmonary arteriovenous malformation development, growth and regression$702,732
R01 · FY2025 · HL · contact PI
Understanding and targeting molecular and cellular events responsible for pulmonary arteriovenous malformation development, growth and regression$688,595
R01 · FY2024 · HL · contact PI
Understanding and targeting molecular as well as structural events governing right ventricular adaptation, failure and recovery in pulmonary hypertension using repurposed drugs$401,078
R01 · FY2024 · HL · contact PI
Vasculata 2024$34,500
R13 · FY2024 · HL · contact PI
Understanding and targeting molecular and cellular events responsible for pulmonary arteriovenous malformation development, growth and regression$696,236
R01 · FY2023 · HL · contact PI
Understanding and targeting molecular as well as structural events governing right ventricular adaptation, failure and recovery in pulmonary hypertension using repurposed drugs$418,412
R01 · FY2023 · HL · contact PI
Understanding and targeting molecular as well as structural events governing right ventricular adaptation, failure and recovery in pulmonary hypertension using repurposed drugs$411,831
R01 · FY2022 · HL · contact PI
Understanding and targeting molecular as well as structural events governing right ventricular adaptation, failure and recovery in pulmonary hypertension using repurposed drugs$419,332
R01 · FY2021 · HL · contact PI
Targeting Novel BMPR2 modifiers in Pulmonary Hypertension with Repurposed Drugs$436,538
R01 · FY2020 · HL · contact PI
Targeting Novel BMPR2 modifiers in Pulmonary Hypertension with Repurposed Drugs$436,538
R01 · FY2019 · HL · contact PI
Targeting Novel BMPR2 modifiers in Pulmonary Hypertension with Repurposed Drugs$436,538
R01 · FY2018 · HL · contact PI
Targeting Novel BMPR2 modifiers in Pulmonary Hypertension with Repurposed Drugs$396,649
R01 · FY2017 · HL · contact PI
Targeting Novel BMPR2 modifiers in Pulmonary Hypertension with Repurposed Drugs$397,562
R01 · FY2016 · HL · contact PI
Modulating BMPRII Signaling in Pulmonary Arterial Hypertension$121,236
K08 · FY2015 · HL · contact PI
Modulating BMPRII Signaling in Pulmonary Arterial Hypertension$121,236
K08 · FY2014 · HL · contact PI
Modulating BMPRII Signaling in Pulmonary Arterial Hypertension$121,236
K08 · FY2013 · HL · contact PI
Modulating BMPRII Signaling in Pulmonary Arterial Hypertension$121,236
K08 · FY2012 · HL · contact PI
Modulating BMPRII Signaling in Pulmonary Arterial Hypertension$121,236
K08 · FY2011 · HL · contact PI